IPO Boot Camp

IPO MARKET UPDATE | 9:00 – 9:45 am

Jim Cooney | Bank of America Merrill Lynch | jim.cooney@baml.com

Jim Cooney is a Managing Director in the Equity Capital Markets Americas Group at Bank of America Merrill Lynch and has been with the firm for 19 years. Based in New York, Jim has sector responsibility for the firm's health care clients, including the origination and execution of all equity and equity-linked transactions within this vertical. Jim has executed over 500 bookrun transactions for issuers across all products since joining Equity Capital Markets in 1998. His expertise covers Initial Public Offerings, Marketed Add-on and Secondary Offerings, Accelerated Global Tenders, Block Trades, Convertible & Exchangeable Bonds, as well as Corporate Derivatives.

Prior to joining ECM, Jim spent two years in Merrill Lynch's Industrials Investment Banking Group covering a wide range of strategic and financing assignments. His international experience includes a six-month rotation in 2000 in Equity Capital Markets in Hong Kong. Jim graduated with Honors receiving a B.S. in Finance from The Pennsylvania State University.

Doug Baird | Citi | doug.baird@citi.com

Mr. Baird is Chairman of Citi's Equity Capital Markets business where he is responsible for the origination, structuring and execution of equity and equity-linked financing transactions for the Bank's corporate clients. He has 25+ years' experience in initial public offerings, follow-on financings, convertible debt and preferred offerings, registered block trades, dutch auction repurchases and other transactions involving the public equity markets. He is also involved in the Firm's equity private placement business including PIPEs, registered direct offerings and Reg D placements.

Mr. Baird received his A.B. and M.B.A. from Dartmouth College after graduating from Deerfield Academy.

Goksu Yolac | J.P. Morgan | goksu.yolac@jpmorgan.com

Goksu Yolac is a Managing Director and Head of Diversified Industries Equity Capital Markets at J.P. Morgan. She is responsible for the ECM coverage of Diversified Industries, which includes Homebuilding, Building Products, Real Estate Services, Transportation & Logistics, Aerospace & Defense, Autos, Chemicals and Industrials.

Previously, Ms. Yolac worked with Technology, Media and Telecom clients. She joined J.P. Morgan in 1998. Ms. Yolac holds a B.A. in Finance & Economics from Georgetown University.

John Meade | Davis Polk | john.meade@davispolk.com

Mr. Meade is a partner in Davis Polk's Capital Markets Group, representing issuer and underwriter clients in public and private securities offerings for U.S. and non-U.S. corporations. He also advises on general corporate matters, including corporate governance and SEC reporting matters.

John's recent experience includes advising on the IPOs of Synchrony Financial, Hilton Worldwide and Manchester United. John practiced in Davis Polk's London office from 2003 to 2011, where he worked on cross-border financings and other corporate transactions, including IPOs in Europe, Africa and Asia.

LATE STAGE PRIVATE PLACEMENTS AND CROSS-OVER ROUNDS | 9:45 - 10:45 am

Valerie Wong Fountain | Morgan Stanley | valerie.a.wong@morganstanley.com

Valerie Wong Fountain is a Managing Director at Morgan Stanley based in the firm's New York office. Valerie is Co-Head of Private Capital Markets, a dedicated platform within Institutional Securities focused on raising capital for corporations in private market transactions. Valerie partners closely with investment banking to advise companies across multiple sectors on all matters related to their private funding goals. In addition, she manages the private syndicate, connecting institutional pools of capital with high quality issuers on a global basis.

In her prior role, she served as Chief of Staff to James Gorman, Morgan Stanley's Chairman and Chief Executive Officer. She was responsible for managing the CEO's office and Firm management staff; liaising with senior executives, coverage officers, and clients on behalf of the CEO; driving key strategic projects and initiatives; and covering key clients across geographies as a firm relationship manager. Previously, she was a trader in the Institutional Equity Division, where she traded a range of Delta One products including Exchange-Traded Products, Index and Custom Basket Total Return Equity Swaps, Futures, and Program Baskets.

Valerie serves on the First Tee of Metropolitan New York Young Benefactors Board, and the Penn Golf Alumni Board, where she co-chairs the Mentoring Committee. She is an active participant and leader of Morgan Stanley-related community affairs and philanthropic efforts. In addition, she recently completed a two-year term as Morgan Stanley's Corporate Leader for the Council on Foreign Relations. Valerie earned a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania, graduating *summa cum laude* and as a University and Joseph Wharton Scholar. She was also a Division I athlete, competing as a three-year letterwinner on the Women's Varsity Golf Team. Valerie also holds the Chartered Financial Analyst designation.

Jonathan Fassberg | Trout Group | ifassberg@troutgroup.com

Jonathan Fassberg is a visionary entrepreneur who recognized early in his 20-year career that small-cap biotechnology companies were underserved in an investor relations capacity. To fill this void, Mr. Fassberg founded The Trout Group, the leading investor relations firm in the life sciences industry, and serves as Chief Executive Officer. Trout has served over 250 public and private companies from its six offices around the world. Trout's clients also had challenges accessing capital, leading Mr. Fassberg to start Trout Group's sister company, Trout Capital LLC, in 2004 to assist clients in a financial advisory role. Prior to founding Trout in 1996, Jonathan was a sell-side analyst at a health care-focused investment bank.

Before his career on Wall Street, Jonathan spent four years at DuPont Pharma in various sales and marketing positions. Jonathan holds a Bachelor of Science degree in biology and chemistry from The University of North Carolina – Chapel Hill and a Master of Business Administration degree in finance from New York University's Stern School of Business. He also holds Series 7, 24, 79 and 63 securities licenses. Jonathan has been an active member of Young Presidents Organization since joining the Manhattan Chapter in 2007 and is currently serving as Chapter Chair. He also sits on the board of directors for the Carolina Center for Jewish Studies at UNC.

John Buttrick | Union Square Ventures | john@usv.com

John Buttrick is a partner at Union Square Ventures, joining the firm in 2010, where his investments include Lending Club, C2FO, SigFig, Eshares. He began his career in 1985 as a mergers and acquisitions lawyer at Davis Polk & Wardwell in the New York and Paris offices.

From 2000 to 2004, John was a partner at LiveWire, a private equity group that acquired and managed back-office software companies. Between 2004 and 2010, he was involved in a number of start-up ventures in the U.S. and Europe as an investor, director and consultant.

Sophia Hudson | Davis Polk | sophia.hudson@davispolk.com

Ms. Hudson is a partner in Davis Polk's Capital Markets Group. She advises U.S. and non-U.S. issuers and underwriters, including all of the major U.S. investment banks, on initial public offerings and other equity offerings, public and private high-yield, investment-grade and convertible debt offerings and private placements of equity and convertible securities for early-stage companies. She also advises her corporate clients on governance, corporate and securities law matters. Ms. Hudson's experience ranges across a variety of industries, including biotech, specialty pharmaceuticals, consumer, financial institutions, industrials and mining.

Sophia's recent transactional experience includes advising the issuers on the IPOs of Affimed Therapeutics, Auris Medical, Biotie Therapies and Prosensa, and advising the underwriters on the IPOs of REGENXBIO, ConforMIS, Galapagos, EndoChoice, Evolent, PTC Therapeutics, Spark Therapeutics, Summit Materials and Wesco Aircraft.

IPO READINESS: ACCOUNTING AND ADVISORY | 11:00 – 11:45 am

Mike Gould | PwC | mike.gould@us.pwc.com

Mike is a Capital Markets partner at PwC with 25 years of experience providing accounting, financial reporting and advisory services, while based in the United States, South Korea, and the United Kingdom.

Mike leads our Public Offerings services practice in the U.S., where he helps his clients access the debt and equity capital markets in the US, by providing them with technical and project management advice on accounting and financial reporting issues associated with the SEC registration process, Initial Public Offerings ("IPOs"), 144a debt and equity offerings, divestitures and carve-outs, and conversions to and from IFRS and US GAAP.

Mike's specific technical knowledge focuses on accounting for carve-outs, purchase accounting, pro forma financial statements, stock compensation, principles of revenue recognition, segmental reporting, the SEC registration process and private equity exit strategies. As a result, he frequently takes on the role of an "IPO Advisor" to help his clients both with their initial registration process, and also with the process of preparing to operate as a public company.

Mike also started and now leads the Capital Markets Advisor (CMA) business within PwC in the US, to provide clients with independent and objective advice on capital structure, capital markets, and valuation issues critical to achieving corporate objectives and positioning the company for success.

During his career, Mike has worked on over 100 IPOs and similar transactions, for both large, as well as IPOs of many smaller and mid-cap privately-held companies for private equity and other sponsors. He has worked across a variety of industries, with an emphasis on fast growing technology, pharmaceutical and medical device and consumer goods companies.

Daniel Klausner | PwC | daniel.h.klausner@pwc.com

Daniel joined PwC in 2015 to lead our IPO efforts in our Capital Markets Advisory practice, focusing on advising companies on equity capital alternatives, structure of the IPO, investment bank and equity research analyst selection, development of the equity story, preliminary independent views on valuation, sizing, target investors, timing and the IPO/ equity raising process in general. Daniel advises companies with their equity capital markets decisions as an "Independent Advisor" to work with companies to navigate the capital markets.

Prior to joining PwC, Daniel was Head of Equity Corporate Finance, Americas in Equity Capital Markets Origination at UBS Investment Bank where he led the origination and execution of lead-managed equity products. He advised clients on structuring, capitalization, projections, pre-IPO readiness, due diligence, corporate governance, timing, positioning, valuation and pricing strategy. Daniel has advised 100+ clients on more than \$150 billion of financings across a wide array of strategic financing activities including IPOs, follow-on offerings, carve-outs, spinoffs, block-trades, equity-linked and private placements. He also brings broad expertise across a range of industries including healthcare/biotech, oil and gas, consumer and retail, financial institutions, industrials, technology and media.

At UBS Investment Bank, Daniel was a permanent member of the Equity Commitment Committee which approved all lead-managed bookrun equity transactions. Daniel previously worked at Morgan Stanley and Merrill Lynch in Investment Banking. He also worked at FTI Capital Advisors. Daniel is licensed with FINRA (Series 24, 7 and 63).

IPO READINESS: STRUCTURE AND TAX | 11:45 am – 12:30 pm

Michael Mollerus | Davis Polk | michael.mollerus@davispolk.com

Mr. Mollerus is a partner in the Tax Group at Davis Polk. His practice centers on advice to corporate and private equity fund clients on mergers, acquisitions, spinoffs and other major transactions, including IPOs and related financings for Prosensa, Affimed, Biotie Therapies, MSCI, Kosmos Energy, Cobalt International Energy, Ally Financial, Delphi Automotive and Markit.

He is also highly regarded for his work advising industry-leading corporate clients and major investment banks on the full gamut of transactional matters, including Roche, Shire, Emerson, Reckitt Benckiser, PartnerRe, Digicel and Cobalt International Energy.

Byron Rooney | Davis Polk | byron.rooney@davispolk.com

Mr. Rooney is a partner in Davis Polk's Capital Markets Group. He represents both corporate and financial institution clients across a broad range of capital markets transactions, including IPOs and other equity offerings, and investment-grade, high-yield and convertible debt financings. He also represents financial investor clients in connection with corporate restructurings and strategic debt financings. His practice also includes advising U.S. public companies on general corporate, securities law and governance matters and startup and other private companies in connection with general corporate and early-stage funding transactions. Mr. Rooney has experience across a variety of sectors, including technology, financial, oil and gas, retail and general industrials.

Byron's transactional experience includes advising the underwriters in connection with the IPOs of First Data, MRC Global and Vantiv, as well as Cobalt International Energy and Kosmos Energy in connection with their IPOs.

Richard Truesdell | Davis Polk | richard.truesdell@davispolk.com

Mr. Truesdell is co-head of Davis Polk's Capital Markets Group. The Financial Times identified him as one of the ten most innovative individuals nationwide in its 2011 "U.S. Innovative Lawyers" special report. He was also named one of the country's three "Most Influential Lawyers" in Finance and Capital Markets by The National Law Journal, which credited him with helping "hoist the economy back to its feet" and named Transatlantic Finance Dealmaker (U.S.) by American Lawyer in 2015.

Mr. Truesdell represents clients in U.S. and international capital markets transactions and advises on corporate governance and securities market regulation. He has represented all of the major U.S. investment banks, as well as a variety of corporate clients. He has extensive experience with a wide variety of both public and private debt and equity offerings by U.S. and non-U.S. issuers, including initial public offerings, convertible offerings and high-yield debt financings.

Mr. Truesdell completed more IPOs by U.S. companies than any other lawyer in each of 2013, 2010 and 2009. Recently completed IPOs include Affimed, Auris Medical, Avolon Holdings, Biotie Therapeutics, ConforMIS, EndoChoice, Evolent Health, First Data, Fogo de Chao, Galapagos, Intrawest Resorts, Markit, Novocure, Performance Sports Group, REGENXBIO and Spark Therapeutics.

UNDERWRITERS AND RESEARCH ANALYSTS | 1:30 – 2:30 pm

Thomas Morrison | Blackstone | thomas.morrison@blackstone.com

Thomas Morrison is a Senior Managing Director in the Blackstone Capital Markets group. Mr. Morrison leads the firm's Equity Capital Markets effort across our investment and advisory businesses. He assists Blackstone's portfolio companies and advisory clients in equity-related situations, and manages the firm's relationships with public equity market investors. Before joining Blackstone in 2011, Mr. Morrison was the Global Head of Equity Capital Markets at Sanford Bernstein, where he was also a member of the Management Committee.

Previously, Mr. Morrison was the Global Head of Equity Syndicate at Bank of America, where he was also a member of the Equities Management Team, the Equity Capital Markets Operating Committee, and the Equity Commitment Committee. Prior to that, Mr. Morrison worked in the Equity Capital Markets groups at Citigroup, Deutsche Bank, and Goldman Sachs. Mr. Morrison received a B.A. from Harvard College, majoring in Economics. He also received an MBA from the Kellogg Graduate School of Management, with majors in Management, Finance, and Marketing. Mr. Morrison also studied at the University of London, University College.

Leaf Gross | KKR | leaf.gross@kkr.com

Leaf Gross is a Director at KKR Capital Markets. He joined the firm in 2013 and is focused on providing equity capital markets advice to clients in the Americas and Europe. Before joining KKR, Mr. Gross was a Vice President at Morgan Stanley in the global consumer & retail investment banking group, where he was involved in a number of corporate advisory transaction.

He started his private equity career at Cambridge Associates and then moved to Citigroup Global Markets. He earned his M.B.A. degree from the University of Michigan after completing his B.A. at the University of Connecticut.

David Landman | Perella Weinberg | dlandman@pwpartners.com

David Landman is Head of Capital Markets Advisory at Perella Weinberg Partners. He joined Perella Weinberg as a partner in 2007. Prior to joining Perella Weinberg, Mr. Landman was a Managing Director at Morgan Stanley, based in London, from 1987 to 2007. Mr. Landman has extensive experience in initial public offerings, government privatizations, stakeholder monetizations and the capital markets, across multiple sectors, countries and regions.

At Morgan Stanley, Mr. Landman was Head of Capital Markets Services in London from 1994 to 2001, was a member of the Equity and Capital Commitment Committees, and was also the Chief Operating Officer for the European Investment Banking Division of Morgan Stanley from 2001 - 2004. Mr. Landman has advised corporate clients, financial institutions, families and trusts in virtually all major sectors on transactions totaling over \$100 billion.

Mr. Landman received an A.B. degree from Wesleyan University with high honors and a joint Masters in Business Administration and Juris Doctor from the University of Chicago Graduate Schools of Business and Law. He is also admitted to the Bar in New York and Connecticut.

Lee Stettner | Solebury | Iss@solecap.com

Lee Stettner is a Managing Director at Solebury. He has worked on Wall Street for twenty five years in a variety of senior roles in both equity capital markets and corporate finance. Before joining Solebury, Lee was a Managing Director in Equity Capital Markets at J.P. Morgan where he was responsible for both the Healthcare and Natural Resources sectors. He also served on the firm's Equity Underwriting Commitment Committee which is responsible for evaluating all aspects of proposed equity transactions. Prior to joining J.P. Morgan, Lee was a Senior Managing Director and Global Head of Equity Capital Markets at Bear Stearns. From 2004 to 2007, Lee was a Managing Director at Deutsche Bank where he a Managing Director and Head of Healthcare Investment Banking and the Equity Capital Markets Group. Prior to Deutsche Bank, he was a Managing Director in the Equity Capital Markets Group at Credit Suisse First Boston, where he was responsible for origination in the Healthcare and Business Services sectors. Lee started his career at Dean Witter and Morgan Stanley, where he worked in the Healthcare Investment Banking Group.

Over the course of his career, Lee originated and bookran over 300 equity transactions, including landmark transactions for HCA, Alcon, Smith International, AEP, Laredo Petroleum, Antero Resources, AES, PPL, Premier Inc. Quintiles Weight Watchers, Quest Diagnostics, Progress Energy, LabCorp, Apache, Human Genome Sciences, HealthEquity, EndoChoice and Teladoc.

Lee graduated with a BA in Economics from Hamilton College and an MBA from the Wharton School of Business of the University of Pennsylvania. Lee lives in Manhattan with his wife and two daughters.

John Crowley | Davis Polk | john.crowley@davispolk.com

Mr. Crowley is a partner in Davis Polk's Capital Markets Group. He has significant experience in public and private securities offerings in domestic and international markets. He was based in the Hong Kong office from 2001 to 2007 and advised on several of the most significant transactions in Asia. Since returning to the New York office, Mr. Crowley has worked on a wide range of securities offerings, including initial public offerings, follow-on equity, convertible securities, high-yield and investment-grade debt offerings and acquisition financings.

IPO READINESS: CORPORATE GOVERNANCE, DOCUMENTATION AND EXECUTION | 2:30 – 3:15 pm

Michael Kaplan | Davis Polk | michael.kaplan@davispolk.com

As co-head of Davis Polk's global Capital Markets Group, Mr. Kaplan regularly works for issuers and underwriters in connection with capital markets and leveraged finance transactions, including initial public offerings and other equity offerings, as well as offerings of convertible and high-yield debt. He has worked on offerings involving issuers from a variety of industries ranging from technology and telecommunications to basic industry. Mr. Kaplan also regularly advises investment banking clients on securities law-related matters and corporate clients on general corporate matters, including corporate governance, SEC and Sarbanes-Oxley matters. Mr. Kaplan was named an "AmLaw Dealmaker of the Year" in 2012 for his work advising Delphi Automotive PLC on its IPO.

Mr. Kaplan's recent transactional experience includes advising on IPOs for Hilton Hotels, Israel Chemicals Ltd., Summit Materials, Inc., Virtu Financial, Inc., Coty Inc., Kamada Ltd., Taminco Corporation, U.S. Silica Corporation, Delphi Automotive PLC, IoanDepot, Inc., Mediamind Inc., and Wesco Aircraft Corporation.

Deanna Kirkpatrick | Davis Polk | deanna.kirkpatrick@davispolk.com

Ms. Kirkpatrick is a partner in Davis Polk's Capital Markets Group. Her practice includes public equity, equity-linked, debt and other securities offerings by U.S. issuers. She has regularly worked for issuers and underwriters in connection with capital markets transactions, including initial public offerings, as well as convertible and exchangeable securities offerings. Ms. Kirkpatrick has worked on offerings for issuers over a broad spectrum of industries, including utilities, financial institutions, health care, oil and gas, retail, media and special-purpose acquisition companies.

Ms. Kirkpatrick's recent transactional experience includes advising on the IPOs of Cynapsus Therapeutics, Capitol Acquisition Corp. III, GP Investments Acquisition Corp., Oxford Immunotec, RE/MAX Holdings, Capitol Acquisition Corp. II and Health Insurance Innovations.

IPO MARKETING | 3:30 – 4:15 pm

Conrad Rubin | Credit Suisse | conrad.rubin@credit-suisse.com

Conrad is a Director and the US Head of Equity Corporate Finance in Equity Capital Markets based in New York. He provides transaction management and oversight for initial public offerings, private placements and special situations arising out of Credit Suisse's equities origination. He transitioned to his current position in ECM after serving as a senior legal advisor to the investment banking division.

Conrad joined Credit Suisse in 2005. Prior to that he was a lawyer at Merrill Lynch where he was a senior advisor to Merrill Lynch's Treasury Office on corporate finance matters (2002 to 2005) and legal advisor to investment banking (2000 to 2002). Previously, he was in private practice in New York and Hong Kong with Brown & Wood LLP (acquired by Sidley Austin LLP).

Conrad has a J.D. from Columbia Law School, an MALD from the Fletcher School and a B.A. from Stanford University.

Olympia McNerney | Goldman Sachs | olympia.mcnerney@gs.com

Olympia is a member of the Equity Capital Markets Group in New York, focused on the origination and execution of equity and equity-linked financings, including initial public offerings, follow-ons, block trades and convertibles for the Natural Resources sector. She works closely with oil and gas; utility and power, chemicals; and metals and mining companies throughout the United States. Previously, Olympia was in Equity Research for two years before joining the Equity Capital Markets Group in 2004. She joined Goldman Sachs in 2002 as an analyst and was named managing director in 2013.

Olympia earned a B.A. in Economics from Princeton University in 2002.

Joseph Hall | Davis Polk | joseph.hall@davispolk.com

Mr. Hall is a partner in the firm's Capital Markets Group and is also head of the firm's corporate governance practice. He works on the full range of capital markets transactions, and advises public companies and regulated entities on corporate governance and financial regulatory compliance. He is a frequent speaker on topics of corporate governance and SEC compliance.

Mr. Hall began his career at Davis Polk in 1989. Between 2003 and 2005 he served at the U.S. Securities and Exchange Commission, ultimately as Managing Executive for Policy under Chairman William H. Donaldson. As a member of Chairman Donaldson's senior management team, Mr. Hall assisted in directing the Commission's policy-making and enforcement activities.

Mr. Hall's recent IPO experience includes advising underwriters and issuers on transactions in the insurance, manufacturing, aircraft leasing, software consulting, biopharma and fintech industries, as well as several closed-end funds. He has advised on closed-end fund IPOs for PIMCO Dynamic Income Fund, ING Emerging Markets High Dividend Equity Fund, Blackstone/GSO Long-Short Credit Income Fund, Eaton Vance Tax-Advantaged Bond and Option Strategies Fund, Blackstone/GSO Senior Floating Rate Term Fund.

INVESTOR RELATIONS

Jeff Grossman | Solebury | jgrossman@soleburyir.com

Jeff Grossman brings over 15 years of Investor Relations and Equity Capital Markets experience to his role leading Solebury Communications Group. Since joining Solebury in 2009, Jeff has led a team that has provided strategic Investor Relations advice and counsel to over 90 companies, crossing numerous sectors, market caps, and timeframes in the corporate lifecycle. These engagements include the development and execution of comprehensive Investor Relations programs, completing numerous IPO and follow-on offerings, deep dive perception audits, strategic IR messaging and planning, investor targeting and driving the process and execution on hundreds of quarterly earnings calls, investor conferences and non-deal roadshows.

Jeff joined Solebury from Citi Global Capital Markets, where he was a member of the equity origination team on the Equity Capital Markets Desk. During his tenure at Citi, Jeff worked on equity and equity linked capital raises in the industrial and financial sectors.

Jeff began his career with The Carson Group, an investor relations consulting / capital markets intelligence firm, where he focused on providing real-time stock surveillance to both corporate and investment banking clients. Jeff left Carson in 2000 to co-found Ilios Partners LLC, an investor relations consulting / capital markets intelligence firm. At Ilios, Jeff was a Partner and a Director for the Investment Banking Services Group, where he worked with 14 equity capital markets desks across Wall Street on hundreds of equity financings.

Jeff earned his MBA from Columbia Business School's Executive Program and his B.A. in Economics from Tufts University. Jeff is also a member of the National Investor Relations Institute (NIRI).

Lee Stern | Trout Group | Istern@troutgroup.com

Lee Stern has a broad array of experience in investor relations, management consulting and finance. Since joining The Trout Group in 1999, he has worked with hundreds of companies, predominantly in the life sciences, to develop and implement their investor positioning strategies and programs. He has assisted private and public companies with investor targeting and capital-raising strategies both in an investor relations and capital markets capacity, and had advised senior management on general company strategy. Lee's responsibilities also include the compliance function of Trout Capital LLC, the firm's broker-dealer.

Prior to his career at Trout, Lee worked at William M. Mercer in the Human Resource Management Consulting group.

Lee holds an MBA from the Wharton School of the University of Pennsylvania and a Bachelor of Science degree in quantitative economics from Tufts University. Lee is also a Chartered Financial Analyst (CFA) and holds Series 7, 24, 79, 63 and 99 securities licenses. He is a member of the CFA Institute, plays drums for a New York-based rock and roll band and enjoys spending any free time with his wife, son and daughter.

Byron Rooney | Davis Polk | byron.rooney@davispolk.com

Mr. Rooney is a partner in Davis Polk's Capital Markets Group. He represents both corporate and financial institution clients across a broad range of capital markets transactions, including IPOs and other equity offerings, and investment-grade, high-yield and convertible debt financings. He also represents financial investor clients in connection with corporate restructurings and strategic debt financings. His practice also includes advising U.S. public companies on general corporate, securities law and governance matters and start-up and other private companies in connection with general corporate and early-stage funding transactions. Mr. Rooney has experience across a variety of sectors, including technology, financial, oil and gas, retail and general industrials.

Byron's transactional experience includes advising the underwriters in connection with the IPOs of First Data, MRC Global and Vantiv, as well as Cobalt International Energy and Kosmos Energy in connection with their IPOs.